TY - JOUR
T1 - Treatment of pyruvate carboxylase deficiency with high doses of citrate and aspartate
AU - Ahmad, Ayesha
AU - Kahler, Stephen G.
AU - Kishnani, Priya S.
AU - Artigas-Lopez, Merce
AU - Pappu, Anuradha S.
AU - Steiner, Robert
AU - Millington, David S.
AU - Van Hove, Johan L.K.
PY - 1999
Y1 - 1999
N2 - A patient with severe pyruvate carboxylase deficiency presented at age 11 weeks with metabolic decompensation after routine immunization. She was comatose, had severe lactic acidemia (22 mM) and ketosis, low aspartate and glutamate, elevated citrulline and proline, and mild hyperammonemia. Head magnetic resonance imaging showed subdural hematomas and mild generalized brain atrophy. Biotin-unresponsive pyruvate carboxylase deficiency was diagnosed. To provide oxaloacetate, she was treated with high-dose citrate (7.5 mol/kg-1/day-1), aspartate (10 mmol/kg-1/day-1), and continuous drip feeding. Lactate and ketones diminished dramatically, and plasma amino acids normalized, except for arginine, which required supplementation. In the cerebrospinal fluid (CSF), glutamine remained low and lysine elevated, showing the treatment had not normalized brain chemistry. Metabolic decompensations, triggered by infections or fasting, diminished after the first year. They were characterized by severe lactic and ketoacidosis, hypernatremia, and a tendency to hypoglycemia. At age 3 1/2 years she has profound mental retardation, spasticity, and grand mal and myoclonic seizures only partially controlled by anticonvulsants. The new treatment regimen has helped maintain metabolic control, but the neurological outcome is still poor.
AB - A patient with severe pyruvate carboxylase deficiency presented at age 11 weeks with metabolic decompensation after routine immunization. She was comatose, had severe lactic acidemia (22 mM) and ketosis, low aspartate and glutamate, elevated citrulline and proline, and mild hyperammonemia. Head magnetic resonance imaging showed subdural hematomas and mild generalized brain atrophy. Biotin-unresponsive pyruvate carboxylase deficiency was diagnosed. To provide oxaloacetate, she was treated with high-dose citrate (7.5 mol/kg-1/day-1), aspartate (10 mmol/kg-1/day-1), and continuous drip feeding. Lactate and ketones diminished dramatically, and plasma amino acids normalized, except for arginine, which required supplementation. In the cerebrospinal fluid (CSF), glutamine remained low and lysine elevated, showing the treatment had not normalized brain chemistry. Metabolic decompensations, triggered by infections or fasting, diminished after the first year. They were characterized by severe lactic and ketoacidosis, hypernatremia, and a tendency to hypoglycemia. At age 3 1/2 years she has profound mental retardation, spasticity, and grand mal and myoclonic seizures only partially controlled by anticonvulsants. The new treatment regimen has helped maintain metabolic control, but the neurological outcome is still poor.
KW - Anaplerotic role
KW - Aspartate
KW - Citrate
KW - Neurological outcome
KW - Pyruvate carboxylase
KW - Treatment
UR - http://www.scopus.com/inward/record.url?scp=0032732587&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0032732587&partnerID=8YFLogxK
U2 - 10.1002/(SICI)1096-8628(19991203)87:4<331::AID-AJMG10>3.0.CO;2-K
DO - 10.1002/(SICI)1096-8628(19991203)87:4<331::AID-AJMG10>3.0.CO;2-K
M3 - Article
C2 - 10588840
AN - SCOPUS:0032732587
SN - 1552-4825
VL - 87
SP - 331
EP - 338
JO - American Journal of Medical Genetics, Part A
JF - American Journal of Medical Genetics, Part A
IS - 4
ER -